214 studies on Liraglutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This comprehensive network meta-analysis provides crucial evidence that Tirzepatide may be the most efficacious pharmacological option for weight management in individuals with obesity who do not have Type 2 Diabetes.…
This study highlights a critical concern: while GLP-1 receptor agonists are highly effective for weight loss, the potential for significant lean muscle mass loss needs careful consideration. Preserving muscle is vital…
This systematic review highlights a novel and potentially impactful therapeutic avenue for patients suffering from Hidradenitis Suppurativa, particularly those with underlying metabolic comorbidities. Repurposing exis…
This comprehensive network meta-analysis provides crucial evidence for the comparative effectiveness of GLP-1 receptor and dual agonists in managing obesity. The findings strongly suggest that tirzepatide offers the m…
This study highlights that not all GLP-1 RAs are interchangeable regarding their safety profiles, providing crucial insights for personalized medicine. Clinicians can use this real-world evidence to make more informed…
These findings are crucial for informing prescribing practices and patient monitoring for individuals on GLP-1 RAs, especially those with pre-existing diabetic eye disease. Given the widespread and increasing use of t…
This research highlights the potent renoprotective capabilities of multi-agonist incretin therapies, particularly Retatrutide, in managing Diabetic Kidney Disease. The superior efficacy of Retatrutide, which targets G…
This comprehensive quantitative comparison provides invaluable evidence for clinicians and patients, offering clear guidance on the expected weight loss from different GLP-1 RAs. The findings underscore the varying po…
This systematic review underscores the rapid evolution of pharmacotherapy for obesity, offering unprecedented hope for effective and substantial weight management. The identified therapies, particularly multi-agonist …
This comprehensive network meta-analysis provides crucial evidence to guide clinical decision-making, offering a head-to-head comparison of incretin drugs that is often unavailable from direct trials. The finding that…
This study provides crucial, evidence-based insights into the comparative efficacy and safety of available GLP-1 RAs, offering a clear hierarchy of their weight reduction capabilities. The findings highlight that newe…
This systematic review provides compelling evidence for the superior efficacy of semaglutide among current pharmacological options for obesity management. The substantial weight loss achieved with semaglutide, a GLP-1…
Antiobesity medications offer a dual therapeutic strategy for managing both obesity and the often-coexisting MASLD, a condition with limited approved treatments. This review highlights their potential to become a corn…
This comprehensive review highlights the transformative potential of anti-obesity drugs in managing and potentially reversing MASLD, moving beyond mere lifestyle interventions to address underlying liver pathology. Th…
This comprehensive review highlights the significant therapeutic potential of GLP-1 agonists as a multi-faceted treatment for PCOS, addressing not only metabolic dysfunction like insulin resistance and obesity but als…